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Abstract A quantitative method for detection of amyloid L
peptides using immunoprecipitation-HPLC-mass spectrometry
(IP-LC-MS) is described. Comparison of IP-LC-MS with
sandwich ELISA revealed comparable results in the analysis of
AL 1^40 and AL 1^42 derived from fetal guinea pig cell media
and cell lysates. The use of IP-LC-MS not only allows a
quantitative method for AL 1^40 and AL 1^42 peptides present in
Alzheimer’s disease (AD), but allows detection of other AL
peptide species that may also play a role in the onset of AD in
humans.
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1. Introduction
Alzheimer’s disease (AD) is the major cause of senile de-
mentia in late adult life [1]. Although this neurodegenerative
disease is prevalent among the older population, de¢nitive
clinical diagnosis has proven very di⁄cult. This, in part, is
due to the lack of a simple physiological test for detection
of the disease, as well as the close similarity of AD symptoms
with those observed in other forms of dementia. Post-mortem
examination of AD brain tissue reveals gross histopathologi-
cal changes compared with ‘normal’ brain tissue [2]. However,
the etiology of these changes, as in the deposition of the
amyloid L peptide (AL) to form senile plaques [3], is not
well understood. In order to understand such changes, model
cell systems and transgenic animals [4,5] have been developed
to mimic genetically transmitted forms of the disease. Un-
fortunately, investigation of such model systems has been
hampered by the lack of a sensitive, speci¢c, and robust assay
capable of detecting these changes both intra- and extracellu-
larly.
Enzyme linked immunosorbent assays (ELISAs) [6] and
sandwich ELISAs [7] (sELISAs) have been developed for
the quantitative analysis of individual AL peptides (typically
AL 1^40 and AL 1^42) [8^10]. Unfortunately these assays are
unable to detect AL peptides derived from cell lysates with
any great success. Moreover, subtle chemical changes to the
peptides, which may have a dramatic e¡ect on their physical
and biological properties, cannot be evaluated by this ap-
proach. Identi¢cation of such modi¢cations is vital since
changes in the physical and biological properties of these pep-
tides may play a part in the onset of the disease. Furthermore,
it has been previously shown by Orlando et al. [11] that typ-
ical methods of extracting AL from plaques and brain tissue
often causes covalent modi¢cation of the peptides. These
changes may a¡ect the reliability of ELISA-based quantita-
tion results. Finally, ELISA-based assays can only detect an-
alytes for which antibodies have been raised. This obviously
requires prior knowledge of sample composition coupled with
the time-consuming e¡ort required to raise a new antibody for
each target species. All of these facts prevent ELISA-based
assays from being able to identify unknown species within a
sample.
In order to complement the limited information yielded by
ELISA or sELISA analysis, we have developed an assay based
on quantitative mass spectrometry (MS). Mass spectrometry
is often the detection system of choice for structural character-
ization of analytes within complex biological mixtures [12^15]
due to its ability to speci¢cally detect a wide range of analyte
types. This makes MS ideal for the identi¢cation of unknown
species during de novo research. Furthermore, quantitation of
detected species can be completed simply using either internal
or external calibrants. Finally, MS analysis a¡ords rapid and
sensitive detection of a wide range of compounds at the low
femtomole to high attomole range.
To achieve high sensitivities for analytes derived from com-
plex sample matrices, we have employed immunoprecipitation
(IP) in conjunction with on-line HPLC with MS detection (IP-
LC-MS). This facilitates minimum sample handling while
maximizing the e⁄ciency of analyte capture and concentra-
tion. IP-MS analysis of AL peptides has been demonstrated
previously by Wang et al. [16]; however, this approach was
only capable of examining conditioned cell media. Our new
on-line IP-LC-MS assay has allowed analysis and quantita-
tion of cellular concentration levels of AL peptide directly
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from cell lysates. This assay is, therefore, highly relevant to
the analysis of model AD systems, both in vitro and in vivo,
and may help elucidate the cascade of events leading to AL
deposition and plaque formation. The assay could also ¢nd
major use in determining the e⁄cacy of drug therapies de-
signed to lower AL production within such model systems.
2. Materials and methods
2.1. Materials
Synthetic AL 1^40 and AL 1^42 were purchased from Bachem
California Inc. (Torrance, CA, USA). BAN-50 anti-AL 1^16 antibod-
ies were a gift from N. Suzuki (Takeda Chemical Industries, Osaka,
Japan). Toyopearl beads, phosphate bu¡ered saline (PBS), acetic acid,
and formic acid were bought from Sigma Chemical Co. (St. Louis,
MI, USA). All solvents were purchased from Burdick and Jackson
(Muskegon, MI, USA) and were of analytical grade or better.
2.2. Cell lysis and immunoprecipitation of AL peptides
Approximately 107 fetal guinea pig brain cells were raised to con-
£uence in a 2 cm dish. They were then harvested and lysed with 2%
SDS. The lysate was diluted with 10URIPA bu¡er to reduce the ¢nal
SDS concentration. It should be noted that cell media was removed
prior to addition of SDS. Hence, cell media was not subjected to SDS
contact but was subsequently prepared in an identical manner to cell
lysate.
BAN-50 anti-AL 1^16 antibodies were covalently bound to Toyo-
pearl AF Tresyl 650 M resin beads as per the manufacturer’s instruc-
tions [17]. This process has been described in detail elsewhere [10].
Subsequently, 10 Wl of antibody-bound beads were added either to
V200 Wl of cell media or V200 Wl cell lysate with gentle rocking at
4‡C for 24 h. The beads were removed and washed 2U with 4‡C PBS.
2.3. Elution of aL peptides
Peptide antigens were eluted from the antibody Toyopearl beads
(10 Wl) with 20 Wl of 60:40 CH3CN:H2O and stirred gently every 10
min. After 1 h of this procedure, 0.5 Wl glacial acetic acid was added
and, subsequently, stirred and allowed to stand for 5 min at room
temperature. In order to load the peptide antigens onto the HPLC
column, the organic solution (60:40 CH3CN:H2O) was diluted with
40 Wl deionized H2O. The supernatant was drawn up into a syringe
and loop-injected onto a C-8 reversed phase HPLC column.
2.4. HPLC conditions
A UMA HPLC system (Michrom Bioresources Inc., Auburn, CA,
USA) ¢tted with a C-8 column (50 mmU0.5 mm, monitor C-8 pack-
ing material, Michrom Bioresources Inc.) was utilized for all HPLC
analyses. A gradient of 20% mobile phase B (90% CH3CN/7% water/
3% n-propanol (n-PrOH)/0.5% acetic acid (AcOH)/0.2% tri£uoroacet-
ic acid (TFA)), 80% mobile phase A (2% CH3CN/98% water/0.5%
AcOH/0.15 TFA) to 70% mobile phase B reached over 15 min at a
£ow rate of 30 Wl/min was utilized giving an estimated gradient delay
of 4 min.
2.5. Mass spectrometry conditions
A Finnigan MAT 900 double sector instrument ¢tted with a posi-
tion and time resolved ion counter (PATRIC) array detector was
utilized for all MS analyses. The MS instrument was operated over
a mass range of 700^1200 Da at a scan rate of 2 s/decade. The
PATRIC detector was operated at a microchannel voltage of 820 V
and a mass window of 8%. Eluent from the HPLC column was in-
troduced into the MS via a fused silica capillary (180 Wm ODU25 Wm
ID, Polymicro Technologies, Phoenix, AZ, USA) which passed co-
axially through the inner bore of the electrospray needle. This needle
was biased at 4.8 kV with respect to the accelerating voltage of 5 kV.
Ionization was by positive ion electrospray ionization with an N2
sheath gas £ow to help nebulization (1.5 l/min).
2.6. Calibration curve construction
Calibration curves for human AL 1^40 and 1^42 were constructed
using known amounts of the two synthetic peptides bound to BAN-50
anti-AL 1^16 beads. The antigens were eluted from the beads and
analyzed by LC-MS using the identical protocol employed with bio-
logically derived samples. Synthetic human AL 1^40 and 1^42 pep-
tides were exposed to the beads at amounts ranging from 100 fmol,
200 fmol, 300 fmol, 500 fmol, 700 fmol, 1000 fmol and 3000 fmol for
both peptides. Each calibration point was examined in triplicate and
peak areas from the MH44 and MH
5
5 ions combined for each peptide.
Combining the peak areas allowed small variations in charge state
distribution between samples to be averaged out.
3. Results and discussion
3.1. Immunoprecipitation for LC-MS and sELISA
Previous studies have demonstrated the high speci¢city of
the BAN-50 anti-human AL antibody for both synthetic and
endogenous AL peptides [9,10]. The epitope region has been
determined to be the ¢rst 16 N-terminal amino acids and a
further requirement is that there is a free amino terminus.
Hence, this antibody was utilized in the IP step in the analysis
of endogenous AL peptides. Since the epitope consists of the
N-terminus of the AL peptides [10], various ragged C-termini
AL peptides would also be isolated (see later). Furthermore,
this antibody had been used in a sELISA assay to quantitate
AL 1^40 and AL 1^42 derived from fetal guinea pig cell media
[10,18]. In order to ensure that we could directly compare the
quantitation of AL peptides by IP-LC-MS with ELISA and/or
sELISA, the IP step carried out was identical for both anal-
yses. Suzuki et al. [10] had previously demonstrated that 60:40
CH3CH:H2O a¡orded optimal recovery (V85^90%) of AL
peptides from BAN-50 antibodies. Furthermore, subsequently
Oyagi et al. [18] has shown that, using this approach, total AL
peptide capture and recovery from spiked cell media was
V35^40%. In all the present analyses, samples were subjected
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Fig. 1. Calibration curves for (A) synthetic human AL 1^40 and (B)
AL 1^42 eluted from BAN-50 antibodies bound to Toyopearl resin
beads.
N.J. Clarke et al./FEBS Letters 430 (1998) 419^423420
to IP as described above and then subsequently split 50:50 for
concomitant sELISA and LC-MS analysis respectively.
Calibration curves for quantitation by IP-LC-MS were con-
structed using synthetic AL 1^40 and AL 1^42 peptides. These
peptides were bound to BAN-50 Toyopearl resin beads at
varying amounts ranging from 100^3000 fmol for each pep-
tide. All calibration points were examined in triplicate and a
linear correlation was observed for both peptides over this
concentration range (AL 1^40 r2 = 0.990, AL 1^42 r2 = 0.988)
(Fig. 1). Calibration curves were also validated with spiked
synthetic human AL 1^40 and 1^42 samples. Various concen-
trations of peptide solutions were prepared and analyzed blind
by IP-LC-MS. Results obtained in this way were in very good
agreement with the actual concentrations bound to the beads
( þ 5%, data not shown). These blind tests demonstrated the
inter-run reproducibility of the calibration curves. It can be
seen (Fig. 1) that the calibration curves for both AL 1^40 and
AL 1^42 do not intercept the y-axis at zero. In part, this is due
to low level chemical background. This leads to some signi¢-
cant electronic responses by the ultrasensitive PATRIC detec-
tion of the MAT 900. Ultimately, this results in some en-
hanced baseline response at sample levels below 10^50
femtomoles, and this phenomenon has been observed else-
where [19].
3.2. Quantitation of endogenous AL peptides ^ comparison
IP-LC-MS and IP-sELISA
Cell media and lysate from fetal guinea pig brain cells were
collected separately. Each sample (200 Wl) was then subjected
to IP, and then each was split into two equal volumes. One
half of each sample was quanti¢ed using sELISA, as described
previously [8,10]. The other half of each sample was subjected
to LC-MS analysis and quantitation. In the case of the IP-LC-
MS analysis of 3 day old conditioned cell media abundant ion
responses for both AL 1^40 and AL 1^42 peptides were ob-
served. The data show the selected ion pro¢le (SIP) for the
MH44 1083.5 (Fig. 2A) and MH
4
4 1129.6 (Fig. 2B) for AL 1^
40 and AL 1^42, respectively. The inserts show the summed
raw data from beneath these responses. In both cases the
MH44 and MH
5
5 ions were clearly observed with signal-to-
noise ratios greater than 10:1 for AL 1^40 (Fig. 2A) and 5:1
for AL 1^42 (Fig. 2B). Mathematical transformation of the
detected AL 1^40 and 1^42 peptide ions yielded molecular
weights in excellent agreement with the expected values (AL
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Fig. 3. Results from IP-LC-MS of cell lysate. A: Data for AL 1^40
from the cell lysate. The foreground ¢gure shows the single ion pro-
¢le for the 4 ion from this peptide while the insert shows the
summed raw data from beneath the peak. B: Data for AL 1^42
from the cell lysate. The foreground ¢gure shows the single ion pro-
¢le for the 4 ion from this peptide while the insert shows the
summed raw data from beneath the peak.
Fig. 2. Results from IP-LC-MS of conditioned cell medium. A:
Data for AL 1^40 from conditioned cell medium. The foreground
¢gure shows the single ion pro¢le for the 4 ion from this peptide
while the insert shows the summed raw data from beneath the
peak. B: Data for AL 1^42 from conditioned cell medium. The
foreground ¢gure shows the single ion pro¢le for the 4 ion from
this peptide while the insert shows the summed raw data from be-
neath the peak.
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1^40 Mr, measured 4330.0 Da, expected 4329.9 Da; AL 1^42
Mr, measured 4514.2 Da, expected 4514.1 Da).
A similar analysis of cell lysate (Fig. 3A and B) yielded AL
1^40 and 1^42 responses at signi¢cantly reduced signal ion
abundance. However, it is interesting to note that the relative
intensities of AL 1^42 versus AL 1^40 in the cell lysate
(23:100) were greater than that observed in the conditioned
medium (8:100). This may suggest AL 1^42 is not secreted
from the cell with the same e⁄ciency as AL 1^40. This ob-
servation could also be explained by secreted AL 1^42 forming
¢brils more rapidly than AL 1^40 in cultured medium, thereby
reducing the concentration of free AL 1^42 available for cap-
ture by the antibody. Several studies have suggested this to be
the case in vitro [20,21] and an examination of this property
of AL 1^42 using the new IP-LC-MS assay is ongoing.
It should also be noted that in the LC-MS analysis of the
cell lysates a number of signi¢cant responses eluting after both
AL 1^40 (Fig. 3A) and AL 1^42 (Fig. 3B) can be observed.
However, these same responses are not observed in the LC-
MS analyses of cell media (Fig. 2). Transformation of the raw
MS data contained in each of the peak responses seen in Fig.
3A and B revealed molecular masses corresponding to numer-
ous oligomers of SDS. There were no MS data to indicate
that these responses were possible AL peptide dimers, trimers,
or tetramers. The detection of SDS oligomers only in the cell
lysate is consistent with the fact that the detergent was only
used in cell lysate but not in cell media preparations.
Comparison of the quantitation of AL 1^40 and AL 1^42 in
cell media and cell lysate by IP-LC-MS versus IP-sELISA is
summarized in Table 1. Overall, relatively close agreement
was observed for the two techniques. However, it is notewor-
thy that IP-LC-MS analysis consistently indicated slightly
lower amounts of AL 1^40 and AL 1^42 were present than
determined by IP-sELISA. We believe this may be due to
possible antibody cross reactivity with nontarget materials
leading to some lack of speci¢city in IP-sELISA. It has pre-
viously been noted that ELISA often overestimates analyte
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Fig. 4. Detected AL peptide population from conditioned cell me-
dium. These single ion pro¢les show a representative example of the
various endogenous AL peptides detected within the sample.
Fig. 5. Detected AL peptide population from cell lysate. These sin-
gle ion pro¢les show a representative example of the various endog-
enous AL peptides detected within the sample.
Table 1
A comparison of the results for samples quantitatively measured by sELISA and the new IP-LC-MS assay
Cell medium sELISA Cell medium IP-LC-MS Cell lysate sELISA Cell lysate IP-LC-MS
AL 1^40 3693 fmole 3492 fmole 263 fmole 212 fmole
AL 1^42 371 fmole 320 fmole 42 fmole 6 100 fmole
Cell lysate concentrations of AL 1^42 were below current quantitation levels although detectable AL 1^42 peptide responses were observed.
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amounts compared to on-line chromatography-MS analysis
due to this problem [22].
3.3. Detection of other AL 1^x peptides by IP-LC-MS
An additional powerful feature of IP-LC-MS is the ability
to detect other AL peptides present in both the cell media and
cell lysate. It can be seen in Figs. 4 and 5 that numerous other
components aside from AL 1^40 and 1^42 are present. These
responses were tentatively identi¢ed as AL peptides based on
their detected molecular weights. Fig. 4 shows a selection of
the major MH44 peptide ion responses identi¢ed during the
analysis of a single conditioned media sample. Intense signals
were observed with a very low background noise level. This
clarity of signal is due to the highly e⁄cient capture and
concentration step provided by the immunoprecipitation pro-
tocol in combination with the sample cleanup a¡orded by
HPLC. Fig. 5 shows the identical peptide species detected
within a typical cell lysate sample. As expected, the peptide
concentration is much lower in this sample, and this is re-
£ected in the reduced signal intensity observed for the de-
tected MH44 peptide ions. Indeed, in some cases (e.g. AL 1^
41) it was very di⁄cult to observe a chromatographic re-
sponse for the peptide. However the mass spectral data ob-
tained at the expected retention time allowed tentative identi-
¢cation on the basis of a measured molecular weight. It can
also be seen that numerous other responses are also obtain-
able and, as described earlier, are due to SDS oligomer ions.
Since, at present, there is no de¢nitive proof that a partic-
ular form of AL peptide is solely responsible for the onset
and/or progress of AD, it would seem prudent to observe as
broad a range of endogenous molecules as possible. In this
way new information may be revealed about the cascade of
events leading to formation of senile plaques and the gross
histopathological changes in the AD brain. To complete such
a study using sELISA technology, large numbers of di¡erent
antibodies would be required to detect the myriad family of
possible AL peptides. Such an undertaking would be ex-
tremely di⁄cult and time consuming. The use of a broad-
spectrum detection system such as mass spectrometry, how-
ever, requires only a single well-characterized antibody for the
initial screening and a single MS experiment to detect and
identify all the peptides captured. The results presented here
highlight the e⁄ciency of the new assay in terms of resources,
time, and the sample numbers and volumes required.
4. Conclusions
The newly developed approach of IP-LC-MS provides
quantitative data in good agreement with the previously vali-
dated IP-sELISA approach. In the present analysis, IP-sELI-
SA appears to o¡er a slight advantage in terms of limits of
detection over IP-LC-MS. However, the latest generation of
instruments that are now commercially available o¡er V10^
100-fold enhancement in sensitivity over the MAT 900 used in
the present study, and hence o¡er sensitivity performance
comparable with sELISA assays. However, the speci¢city of
IP-LC-MS for individual AL detection is superior to IP-ELI-
SA and IP-sELISA. Also the £exibility of MS as a detection
system yields much greater information from a single sample
than is possible using the same sELISA assay. The use of on-
line HPLC-MS reduces sample handling to a minimum and
increases the ability to automate this assay allowing examina-
tion of a wider range of compounds within a single experi-
ment. Finally, the use of mass spectrometry should allow the
detection and identi¢cation of modi¢cations to a peptide
(such as point mutations, adduction, phosphorylation or ox-
idation). These factors can all directly a¡ect the behavior of a
peptide and may be crucial in determining the mode of action
for AL peptides within Alzheimer’s disease.
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